By that logic, being challenged more often means that the immune system should have a stronger and longer-lasting response:
The immune system treats any new exposure—be it infection or vaccination—with a cost-benefit threat analysis for the magnitude of immunological memory to generate and maintain. There are resource-commitment decisions: more cells and more protein throughout the body, potentially for decades. Although all of the calculus involved in these immunological cost-benefit analyses is not understood, a long-standing rule of thumb is that repeated exposures are recognized as an increased threat. Hence the success of vaccine regimens split into two or three immunizations.
The response becomes even stronger when challenging the immune system with different versions of the virus, in particular a vaccine and the virus itself (same link).
Heightened response to repeated exposure is clearly at play in hybrid immunity, but it is not so simple, because the magnitude of the response to the second exposure (vaccination after infection) was much larger than after the second dose of vaccine in uninfected individuals. [...] Overall, hybrid immunity to SARS-CoV-2 appears to be impressively potent.
For SARS-CoV-2 this leads to a 25-100x stronger antibody response. It also comes with enhanced neutralizing breadth, and therefore likely some protection against future variants.
Based on this, the article above recommends combining different vaccine modalities such as mRNA (Pfizer, Moderna) and vector (AZ) (see also here).
Lastly, your question may be hard to answer without data, if we extrapolate from a similar question where the answer seems hard to predict in advance:
Additionally, the response to the second vaccine dose was minimal for previously infected persons, indicating an immunity plateau that is not simple to predict.
According to one expert, the immune system essentially makes bets on how often it will face a given virus and how the virus will mutate in the future:
https://science.sciencemag.org/content/372/6549/1392
By that logic, being challenged more often means that the immune system should have a stronger and longer-lasting response:
The response becomes even stronger when challenging the immune system with different versions of the virus, in particular a vaccine and the virus itself (same link).
For SARS-CoV-2 this leads to a 25-100x stronger antibody response. It also comes with enhanced neutralizing breadth, and therefore likely some protection against future variants.
Based on this, the article above recommends combining different vaccine modalities such as mRNA (Pfizer, Moderna) and vector (AZ) (see also here).
Lastly, your question may be hard to answer without data, if we extrapolate from a similar question where the answer seems hard to predict in advance:
I’ll pay $50 for this answer, will message you for payment details.